DaShenLin Pharmaceutical Group Co., Ltd. Class A

DaShenLin Pharmaceutical Group Co., Ltd. Class A

SSSE:603233
20.82
CNY
+0.03
(+0.14%)
1.38EPS
14.47P/E
20.73BMarket Cap
Apr 29Next Earn
DaShenLin Pharmaceutical Group Co., Ltd. Class A
SSE:603233
(Shanghai Stock Exchange)

Recent

price

20.82

P/E

ratio

14.47

div

yld

4.15%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
6.03
5.09
6.22
6.08
6.44
7.3
8.2
10.19
12.87
14.83
18.67
21.66
23.46
24.05
25.37
Revenue per Share
0.28
0.27
0.36
0.46
0.44
0.47
0.49
0.64
0.94
0.7
0.91
1.03
0.81
1.08
1.26
Basic EPS, GAAP
- -
- -
0.26
0.25
0.19
-0.02
0.3
1.1
1.03
0.23
2.39
1.22
1.44
4.25
- -
Free Cash Flow per Basic Share
0.15
0.06
0.44
0.02
0.16
0.02
0.24
0.23
0.29
0.47
0.37
0.53
0.67
0.68
0.86
Dividend per Share
0.61
0.97
0.93
1.05
1.36
2.55
2.82
3.79
4.55
4.81
5.45
5.99
6.06
6.47
6.68
Book Value per Share
0.52
0.88
0.81
0.97
1.16
2.3
2.06
2.57
2.91
2.41
2.76
1.69
1.22
1.68
1.71
Tangible Book Value per Share
539
729
730
867
974
1,016
1,081
1,094
1,133
1,130
1,138
1,133
1,129
1,144
1,133
Basic Weighted Avg Shares
3,252
3,707
4,545
5,265
6,274
7,421
8,859
11,141
14,583
16,759
21,248
24,531
26,497
27,502
28,742
Sales/Revenue/Turnover
8.11
9.25
9.98
11
9.8
9.01
8.34
8.51
9.92
7.13
7.84
7.8
6.08
7.62
8.32
Operating Margin (%)
- -
- -
36
43
55
78
117
143
171
1,149
1,288
1,448
1,602
1,547
- -
Depreciation Expense
149
197
266
395
430
475
532
703
1,062
791
1,036
1,166
915
1,235
1,425
Net Income, GAAP
29.63
29.94
27.23
23.81
25.78
25.21
26.94
24.25
25.12
22.94
23.72
24.4
26.85
26.52
26.19
Effective Tax Rate (%)
4.59
5.33
5.84
7.51
6.86
6.4
6
6.31
7.28
4.72
4.87
4.76
3.45
4.49
4.96
Profit Margin (%)
193
112
9
274
210
1,058
611
1,465
1,971
692
962
-655
-1,121
-1,687
-1,365
Working Capital
- -
10
96
81
29
- -
21
260
3,780
4,204
4,252
4,708
4,542
2,690
2,740
LT Debt
381
590
575
1,021
1,342
2,803
3,087
4,332
5,364
5,936
6,864
7,933
8,138
8,661
8,920
Total Equity
- -
29.4
28.77
33.61
27.13
18.14
15.12
16.74
14.44
7.43
8.92
8.93
6.49
9.03
- -
Return on Invested Capital (%)
- -
26.82
24.53
32.21
29.12
19.29
16.42
18.1
14.24
8.84
8.57
8.47
6.05
7.83
- -
Return on Capital (%)
- -
46.23
51.77
51.99
36.79
23.34
18.36
19.31
22.55
14.85
17.72
17.9
13.33
17.32
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,556
2,864
3,383
LT Borrowings
501
437
777
LT Finance Leases
2,110
2,035
1,963
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,139
1,139
1,139
Market Capitalization
20,249
17,117
20,728

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
13,878
12,793
14,584
Cash, Cash Equivalents & STI
7,111
6,239
7,394
Accounts Receivable, Net
1,271
1,224
1,397
Inventories
4,343
4,180
4,268
Total Current Liabilities
14,968
14,277
15,949
Payables & Accruals
- -
- -
- -
ST Debt
2,556
2,864
3,383
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.54%
10.18%
6.43%
Free Cash Flow
-45.47%
207.28%
198.4%
Net Income, GAAP
14.59%
6.3%
35.04%
Sales/Revenue/Turnover
18.24%
13.79%
3.8%
Total Cash Common Dividend
188.36%
22.25%
3.84%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,752
6,593
6,386
6,766
26,497
2025
6,956
6,567
- -
7,434
27,502
2026
6,973
7,018
7,317
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.23
0.18
0.05
0.81
2025
0.4
0.3
- -
0.14
1.08
2026
0.45
0.37
0.3
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.33
0.02
0.31
0.67
2025
0.01
0.32
- -
0.37
0.68
2026
- -
0.49
- -
- -
- -
Business
DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) is a leading pharmaceutical retail chain operator in China that manufactures, wholesales, and retails a wide range of pharmaceutical and healthcare products, including Chinese and Western patent medicines; ginseng and antler tonic medicinal materials; Chinese herbal pieces; health care products; medical equipment; antibiotics; biochemicals; biologics (excluding vaccines); health foods; nursing supplies; and other commodities such as proprietary Chinese medicines, chemical preparations, and generic and branded drugs. Founded in 1999 and headquartered at No. 410-1, Longxi Avenue, Liwan District, Guangzhou, Guangdong Province, the company employs over 43,000 full-time staff and maintains an extensive chain network across China, with nationwide operations encompassing self-built stores, mergers and acquisitions, franchises, and entry into new markets including Shanghai and Inner Mongolia. In recent developments, DaShenLin has aggressively expanded its store footprint, achieving a net increase of 2,479 stores in 2024 (including 907 self-built, 420 via mergers and acquisitions, and 1,885 franchises, net of closures) and 69 stores in the first quarter of 2025, alongside ongoing store optimization efforts that improve quality, efficiency, and gross margins through refined product portfolios, supply chain integration, and procurement cost reductions; the company also completed an equity buyback of 6.7 million shares (0.59% of capital) for CNY 100.72 million in 2024 and reported revenue of CNY 26.5 billion with net profit of CNY 915 million for 2024, followed by strong first-three-quarters 2025 performance including CNY 20.1 billion in revenue and CNY 1.08 billion in net profit.